NHS
Pan Mersey
Area Prescribing Committee

BOTULINUM NEUROTOXIN TYPE A injection (Xeomin®) for chronic sialorrhoea in children and adolescents

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing BOTULINUM NEUROTOXIN TYPE A injection (Xeomin®) for chronic sialorrhoea in children and adolescents.

GREY

Botulinum neurotoxin type A (Xeomin®) has been granted a license extension and is indicated for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg for chronic sialorrhoea due to neurological / neurodevelopmental disorders.[1]

This recommendation will be reviewed by the Formulary and Guidelines Subgroup review on receipt of an application for use.

In the meantime, clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of chronic sialorrhoea due to neurological / neurodevelopmental disorders in children and adolescents.

- NICE Guideline [NG62]: Cerebral palsy in under 25s: assessment and management, 25 January 2017.
- Pan Mersey APC Guideline: Pharmacological Management of Hypersalivation in Children and Adults, 01 November 2018
- Pan Mersey APC Formulary: 01.02 Antimuscarinics

References

1. Merz Pharma UK Ltd. Summary of Product Characteristics; XEOMIN 50 units powder for solution for injection, 23 September 2021. Accessed online 22 December 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.